ArticleJournal of pharmacopuncture2026
Current Status of Korean Medicine Treatment for Schizophrenia Spectrum Disorders: a nationwide survey of Korean medicine doctors.
Article in Journal of pharmacopuncture, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This study investigated how Korean medicine doctors treat schizophrenia spectrum disorders to assess current practices, identify high-frequency interventions, and evaluate clinical field utilization, aiming to develop evidence-based Korean medicine clinical practice guideline. Methods: A nationwide cross-sectional survey was conducted in December 2024 among doctors affiliated with the Association of Korean Medicine. Korean medicine doctors who had treated schizophrenia spectrum disorder patients within the past six months were included. The survey assessed treatment goals, patient characteristics, treatment modalities, and assessment methods. Results: A total of 324 Korean medicine doctors were included in the final analysis. The most frequently reported treatment objective was management of co-existing symptoms (81.8%), followed by complementary treatment for positive/negative symptoms (44.4%) and management of antipsychotic-induced side effects (29.0%). Patients in the chronic (55.2%) and recovery disease phases (50.6%) were more likely to be treated with Korean medicine than patients with acute exacerbation. Herbal medicine (92.9%) and acupuncture (79.6%) were the primary interventions. The most frequently prescribed herbal formulas were Ondam-tang (61.7%), Shihogayonggolmoryo-tang (57.4%), and Ukgan-san (54.9%). GV20 (82.4%), EX-HN1 (58.0%), and HT7 (44.1%) were the most used acupuncture points. The primary co-existing symptoms managed were insomnia (77.2%), depression (76.2%), and agitation/excitement (64.2%). Weight gain (69.8%), dyspepsia (59.3%), and constipation (55.9%) were the most frequently addressed antipsychotic-induced side effects. Conclusion: This nationwide survey provides foundational data for developing Korean medicine clinical practice guideline for schizophrenia spectrum disorders. The findings revealed that Korean medicine treatment serves a complementary role to conventional antipsychotic medications, primarily focusing on co-existing symptoms and side effect management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.